|
gptkbp:instanceOf
|
nonsteroidal anti-inflammatory drug
|
|
gptkbp:affiliatedWith
|
propionic acid derivatives
|
|
gptkbp:approvalYear
|
1976
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
M01AE02
|
|
gptkbp:availableOn
|
gptkb:tablet
suspension
extended-release tablet
|
|
gptkbp:brand
|
gptkb:Anaprox
gptkb:Naprelan
gptkb:Naprosyn
gptkb:Aleve
|
|
gptkbp:CASNumber
|
22204-53-1
|
|
gptkbp:chemicalFormula
|
C14H14O3
|
|
gptkbp:contraindication
|
peptic ulcer
hypersensitivity to NSAIDs
severe heart failure
|
|
gptkbp:discoveredBy
|
gptkb:Syntex
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
naproxen
|
|
gptkbp:interactsWith
|
gptkb:methotrexate
lithium
ACE inhibitors
diuretics
anticoagulants
other NSAIDs
|
|
gptkbp:IUPACName
|
(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid
|
|
gptkbp:legalStatus
|
prescription
over-the-counter (in some countries)
|
|
gptkbp:mechanismOfAction
|
COX inhibitor
|
|
gptkbp:meltingPoint
|
153°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
230.26 g/mol
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:risk_during_pregnancy
|
may cause harm in third trimester
|
|
gptkbp:routeOfAdministration
|
oral
topical
|
|
gptkbp:sideEffect
|
dizziness
headache
gastrointestinal upset
increased risk of cardiovascular events
|
|
gptkbp:usedFor
|
pain relief
fever reduction
inflammation reduction
treatment of arthritis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:NSAID
gptkb:NSAIDs
gptkb:Bayer_Aleve_(analgesic)
|
|
gptkbp:bfsLayer
|
6
|